ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis
September 28, 2021Innovent Biologics, Group. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer... -
Innovent Announces First Subject Dosed in Trial of Anti-IL-23 Monoclonal Antibody
September 02, 2020Innovent Biologics announced the Phase I clinical study (CIBI112A101) of recombinant anti-interleukin 23p19 subunit antibody injection (IBI112) has completed the first healthy subject dosing in China.
Pharma Sources Insight January 2025
